Skip to main content
Erschienen in: Tumor Biology 4/2015

01.04.2015 | Research Article

Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently

verfasst von: Sateesh Reddy Nallapalle, Sarika Daripally, V. T. S Vidudala Prasad

Erschienen in: Tumor Biology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

We investigated risk association of FAS (−1377 G>A and −670 A>G) and FASL (−844 T>C) promoter polymorphisms with breast, ovarian, cervical, and endometrial cancers and report that the FASL −844 CC genotype was protective against breast, ovarian, cervical, and endometrial cancers (P ≤ 0.01). On the other hand, FAS −1377 GA and AA variants increased risk of breast cancer. However, the GA variant of FAS −1377 was also found to be a risk factor for cervical cancer. In contrast, FAS −670 AG variant significantly lowered risk of breast cancer. Further, we also observed that risk association of co-occurrence of FAS and/or FASL variants with the cancers varied as compared to the presence of individual polymorphisms. Although risk and protective haplotypes of FAS SNPs were observed across the cancer phenotypes, the association of the haplotypes was significant for breast cancer alone with a 3-fold enhanced risk. The protective effect of the FASL CC genotype seen in this study suggests that similar biomolecular mechanisms involving FASL might play a role in female-specific cancers.
Literatur
2.
Zurück zum Zitat Porichi O, Nikolaidou ME, Apostolaki A, Tserkezoglou A, Arnogiannaki N, Kassanos D, et al. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry. Anticancer Res. 2009;29:3977–82.PubMed Porichi O, Nikolaidou ME, Apostolaki A, Tserkezoglou A, Arnogiannaki N, Kassanos D, et al. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry. Anticancer Res. 2009;29:3977–82.PubMed
4.
Zurück zum Zitat Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al. Hereditary ovarian cancer clinical study group; the risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007;104:7–10.CrossRefPubMed Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al. Hereditary ovarian cancer clinical study group; the risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007;104:7–10.CrossRefPubMed
5.
Zurück zum Zitat Nsouli-Maktabi HH, Henson DE, Younes N, Young HA, Cleary SD. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age. Breast Cancer Res Treat. 2011;129:963–9.CrossRefPubMed Nsouli-Maktabi HH, Henson DE, Younes N, Young HA, Cleary SD. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age. Breast Cancer Res Treat. 2011;129:963–9.CrossRefPubMed
6.
Zurück zum Zitat Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, et al. Risk factors for ovarian cancers with and without microsatellite instability. Int J Gynecol Cancer. 2013;23:1010–5.CrossRefPubMedPubMedCentral Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, et al. Risk factors for ovarian cancers with and without microsatellite instability. Int J Gynecol Cancer. 2013;23:1010–5.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58–66.CrossRefPubMed Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58–66.CrossRefPubMed
8.
Zurück zum Zitat Contreras DN, Krammer PH, Potkul RK, Bu P, Rossi JL, Kaufmann AM, et al. Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J Immunother. 2000;23:67–74.CrossRefPubMed Contreras DN, Krammer PH, Potkul RK, Bu P, Rossi JL, Kaufmann AM, et al. Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J Immunother. 2000;23:67–74.CrossRefPubMed
9.
Zurück zum Zitat Ibrahim R, Frederickson H, Parr A, Ward Y, Moncur J, Khleif SN. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer. 2006;106:1065–77.CrossRefPubMed Ibrahim R, Frederickson H, Parr A, Ward Y, Moncur J, Khleif SN. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer. 2006;106:1065–77.CrossRefPubMed
10.
Zurück zum Zitat O’Connell J, Bennett MW, O’Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med. 1997;3:294–300.CrossRefPubMedPubMedCentral O’Connell J, Bennett MW, O’Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med. 1997;3:294–300.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat O’Connell J, Bennett MW, O’Sullivan GC, Roche D, Kelly J, Collins JK, et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol. 1998;186:240–6.CrossRefPubMed O’Connell J, Bennett MW, O’Sullivan GC, Roche D, Kelly J, Collins JK, et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol. 1998;186:240–6.CrossRefPubMed
12.
13.
Zurück zum Zitat Herrnring C, Reimer T, Jeschke U, Makovitzky J, Krüger K, Gerber B, et al. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol. 2000;113:189–94.CrossRefPubMed Herrnring C, Reimer T, Jeschke U, Makovitzky J, Krüger K, Gerber B, et al. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol. 2000;113:189–94.CrossRefPubMed
14.
Zurück zum Zitat Kim Y-S, Kim KH, Choi J-A, Lee JH, Kim HK, Won NH, et al. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas. Arch Pathol Lab Med. 2000;124:687–93.PubMed Kim Y-S, Kim KH, Choi J-A, Lee JH, Kim HK, Won NH, et al. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas. Arch Pathol Lab Med. 2000;124:687–93.PubMed
15.
Zurück zum Zitat Sasaki Y, Hori S, Oda K, Okada T, Takimoto M. Both ETA and ETB receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ETB receptor-deficient rats (aganglionosis rats). Eur J Neurosci. 1998;10:2984–93.CrossRefPubMed Sasaki Y, Hori S, Oda K, Okada T, Takimoto M. Both ETA and ETB receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ETB receptor-deficient rats (aganglionosis rats). Eur J Neurosci. 1998;10:2984–93.CrossRefPubMed
16.
Zurück zum Zitat Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog. 2010;49:944–50.CrossRefPubMed Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, et al. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog. 2010;49:944–50.CrossRefPubMed
17.
Zurück zum Zitat Zhou JH, Chen HZ, Ye F, Lu WG, Xie X. Fas-mediated pathway and apoptosis in control cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncol Rep. 2006;16:307–11.PubMed Zhou JH, Chen HZ, Ye F, Lu WG, Xie X. Fas-mediated pathway and apoptosis in control cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncol Rep. 2006;16:307–11.PubMed
18.
Zurück zum Zitat Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2006;12:5596–602.CrossRefPubMed Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2006;12:5596–602.CrossRefPubMed
19.
Zurück zum Zitat Xu L, Zhou X, Jiang F, Qiu MT, Zhang Z, Yin R, et al. FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects. PLoS One. 2013;8:e74543.CrossRefPubMedPubMedCentral Xu L, Zhou X, Jiang F, Qiu MT, Zhang Z, Yin R, et al. FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects. PLoS One. 2013;8:e74543.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Zhong-Xing Z, Yuan-Yuan M, Hai Zhen M, Jian-Gang Z, Li-Feng Z. FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls. PLoS One. 2013;8:e73700.CrossRefPubMedPubMedCentral Zhong-Xing Z, Yuan-Yuan M, Hai Zhen M, Jian-Gang Z, Li-Feng Z. FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls. PLoS One. 2013;8:e73700.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, et al. Fas gene promoter −670 polymorphism in gynecological cancer. Int J Gynecol Cancer. 2006;16:179–82.CrossRefPubMed Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, et al. Fas gene promoter −670 polymorphism in gynecological cancer. Int J Gynecol Cancer. 2006;16:179–82.CrossRefPubMed
22.
Zurück zum Zitat Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T. Fas −1377 A/G and FasL −844 T/C gene polymorphisms epithelial ovarian cancer. Anticancer Res. 2007;27:991–4.PubMed Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T. Fas −1377 A/G and FasL −844 T/C gene polymorphisms epithelial ovarian cancer. Anticancer Res. 2007;27:991–4.PubMed
23.
Zurück zum Zitat Biggar RJ, Wohlfahrt J, Melbye M. Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. Int J Cancer. 2012;131:716–21.CrossRefPubMed Biggar RJ, Wohlfahrt J, Melbye M. Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. Int J Cancer. 2012;131:716–21.CrossRefPubMed
24.
Zurück zum Zitat Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol. 2004;94:25–32.CrossRefPubMed Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol. 2004;94:25–32.CrossRefPubMed
25.
Zurück zum Zitat Newfield L, Bradlow HL, Sepkovic DW, Auborn K. Estrogen metabolism and the malignant potential of human papillomavirus immortalized keratinocytes. Proc Soc Expt Biol Med. 1998;217:322–6.CrossRef Newfield L, Bradlow HL, Sepkovic DW, Auborn K. Estrogen metabolism and the malignant potential of human papillomavirus immortalized keratinocytes. Proc Soc Expt Biol Med. 1998;217:322–6.CrossRef
26.
Zurück zum Zitat Jaita G, Candolfi M, Zaldivar V, Zárate S, Ferrari L, Pisera D, et al. Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. Endocrinology. 2005;146:4737–44.CrossRefPubMedPubMedCentral Jaita G, Candolfi M, Zaldivar V, Zárate S, Ferrari L, Pisera D, et al. Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. Endocrinology. 2005;146:4737–44.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Li H, Guo HY, Sun T, Zhou YF, Lin DX, Zhang WH, et al. Association between Fas/Fas L genes promoter polymorphisms and pathogenic risk of cervical cancer. Zhonghua Zhong Liu Za Zhi. 2009;31:38–41.PubMed Li H, Guo HY, Sun T, Zhou YF, Lin DX, Zhang WH, et al. Association between Fas/Fas L genes promoter polymorphisms and pathogenic risk of cervical cancer. Zhonghua Zhong Liu Za Zhi. 2009;31:38–41.PubMed
28.
Zurück zum Zitat Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007;28:2548–51.CrossRefPubMed Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007;28:2548–51.CrossRefPubMed
29.
Zurück zum Zitat Kang S, Dong SM, Seo SS, Kim JW, Park SY. FAS −1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008;180:1–5.CrossRefPubMed Kang S, Dong SM, Seo SS, Kim JW, Park SY. FAS −1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008;180:1–5.CrossRefPubMed
30.
Zurück zum Zitat Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005;99:113–8.CrossRefPubMed Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005;99:113–8.CrossRefPubMed
31.
Zurück zum Zitat Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, et al. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes. 2009;2:238.CrossRefPubMedPubMedCentral Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, et al. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes. 2009;2:238.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and breast cancer—pilot study of 134 cases. PLoS One. 2013;8:e53075.CrossRefPubMedPubMedCentral Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and breast cancer—pilot study of 134 cases. PLoS One. 2013;8:e53075.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 2012;3:625–8.PubMed Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 2012;3:625–8.PubMed
34.
Zurück zum Zitat KordiTamandani DM, Sobti RC, Shekari M. Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol. 2008;35:183–6. KordiTamandani DM, Sobti RC, Shekari M. Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol. 2008;35:183–6.
35.
Zurück zum Zitat Zucchi F, da Silva ID, Ribalta JC, de Souza NC, Speck NM, Girão MJ, et al. Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol. 2009;30:142–4.PubMed Zucchi F, da Silva ID, Ribalta JC, de Souza NC, Speck NM, Girão MJ, et al. Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol. 2009;30:142–4.PubMed
36.
Zurück zum Zitat Mellemkjaer L, Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285–92.CrossRefPubMed Mellemkjaer L, Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285–92.CrossRefPubMed
37.
Zurück zum Zitat Molina-Montes E, Pollán M, Payer T, Molina E, Dávila-Arias C, Sánchez MJ. Risk of second primary cancer among women with breast cancer: a population-based study in Granada (Spain). Gynecol Oncol. 2013;130:340–5.CrossRefPubMed Molina-Montes E, Pollán M, Payer T, Molina E, Dávila-Arias C, Sánchez MJ. Risk of second primary cancer among women with breast cancer: a population-based study in Granada (Spain). Gynecol Oncol. 2013;130:340–5.CrossRefPubMed
38.
Zurück zum Zitat Cano A, Serra V, Rivera J, Monmeneu R, Marzo C. Expression of estrogen receptors, progesterone receptors, and an estrogen receptor-associated protein in the human cervix during the menstrual cycle and menopause. Fertil Steril. 1990;54:1058–64.CrossRefPubMed Cano A, Serra V, Rivera J, Monmeneu R, Marzo C. Expression of estrogen receptors, progesterone receptors, and an estrogen receptor-associated protein in the human cervix during the menstrual cycle and menopause. Fertil Steril. 1990;54:1058–64.CrossRefPubMed
39.
Zurück zum Zitat Chaudhuri B, Crist KA, Mucci SJ, Thomford NR, Chaudhuri PK. Estrogen receptor in carcinoma in situ of the cervix. J Surg Oncol. 1992;49:103–6.CrossRefPubMed Chaudhuri B, Crist KA, Mucci SJ, Thomford NR, Chaudhuri PK. Estrogen receptor in carcinoma in situ of the cervix. J Surg Oncol. 1992;49:103–6.CrossRefPubMed
40.
Zurück zum Zitat Song J, Rutherford T, Naftolin F, Brown S, Mor G. Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells. Mol Hum Reprod. 2002;8:447–55.CrossRefPubMed Song J, Rutherford T, Naftolin F, Brown S, Mor G. Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells. Mol Hum Reprod. 2002;8:447–55.CrossRefPubMed
41.
Zurück zum Zitat Zahid M, Beseler CL, Hall JB, LeVan T, Cavalieri EL, Rogan EG. Unbalanced estrogen metabolism in ovarian cancer. Int J Cancer. 2014;134:2414–23.CrossRefPubMedPubMedCentral Zahid M, Beseler CL, Hall JB, LeVan T, Cavalieri EL, Rogan EG. Unbalanced estrogen metabolism in ovarian cancer. Int J Cancer. 2014;134:2414–23.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey Jr JV, Cauley JA, et al. Brinton LA; B∼FIT Research Group. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B∼FIT. Carcinogenesis. 2014;35:346–55.CrossRefPubMed Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey Jr JV, Cauley JA, et al. Brinton LA; B∼FIT Research Group. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B∼FIT. Carcinogenesis. 2014;35:346–55.CrossRefPubMed
43.
Zurück zum Zitat Folkerd E, Dowsett M. Sex hormones and breast cancer risk and prognosis. Breast. 2013;2:S38–43.CrossRef Folkerd E, Dowsett M. Sex hormones and breast cancer risk and prognosis. Breast. 2013;2:S38–43.CrossRef
44.
Zurück zum Zitat Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in control and neoplastic cells. Lab Invest. 1993;69:415–29.PubMed Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in control and neoplastic cells. Lab Invest. 1993;69:415–29.PubMed
45.
Zurück zum Zitat Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, et al. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev. 2014;23:755–64.CrossRefPubMedPubMedCentral Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, et al. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev. 2014;23:755–64.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013;25:368–87.CrossRefPubMed Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013;25:368–87.CrossRefPubMed
47.
Zurück zum Zitat Fambrini M, Buccoliero AM, Pieralli A, Andersson KL, Mattei A, Scarselli G, et al. Tamoxifen, endometrial cancer risk and liquid based cytology. A paradigmatic case. Minerva Ginecol. 2011;63:465–70.PubMed Fambrini M, Buccoliero AM, Pieralli A, Andersson KL, Mattei A, Scarselli G, et al. Tamoxifen, endometrial cancer risk and liquid based cytology. A paradigmatic case. Minerva Ginecol. 2011;63:465–70.PubMed
48.
Zurück zum Zitat Jones ME, van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, van Boven H, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 2012;14:R91.CrossRefPubMedPubMedCentral Jones ME, van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, van Boven H, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 2012;14:R91.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Miller S, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:3. Miller S, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:3.
50.
Zurück zum Zitat Kriplani A, Banerjee K. An overview of age of onset of menopause in northern India. Maturitas. 2005;52:199–204.CrossRefPubMed Kriplani A, Banerjee K. An overview of age of onset of menopause in northern India. Maturitas. 2005;52:199–204.CrossRefPubMed
51.
Zurück zum Zitat Kapur P, Sinha B, Pereira BM. Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale. Menopause. 2009;16:378–84.CrossRefPubMed Kapur P, Sinha B, Pereira BM. Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale. Menopause. 2009;16:378–84.CrossRefPubMed
52.
Zurück zum Zitat Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28:1067–73.CrossRefPubMed Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28:1067–73.CrossRefPubMed
53.
Zurück zum Zitat Li Y, Hao YL, Kang S, Zhou RM, Wang N, Qi BL. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol. 2013;128:584–9.CrossRefPubMed Li Y, Hao YL, Kang S, Zhou RM, Wang N, Qi BL. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol. 2013;128:584–9.CrossRefPubMed
54.
Zurück zum Zitat Zeng J, Fang Y, Li P. FAS-1377 A/G polymorphism in breast cancer: a meta-analysis. Tumour Biol. 2014;35:2575–81.CrossRefPubMed Zeng J, Fang Y, Li P. FAS-1377 A/G polymorphism in breast cancer: a meta-analysis. Tumour Biol. 2014;35:2575–81.CrossRefPubMed
55.
Zurück zum Zitat Li K, Li W, Zou H, Zhao L. Association between FAS 1377 G>A polymorphisms and breast cancer susceptibility: a meta-analysis. Tumour Biol. 2014;35(1):351–6.CrossRefPubMed Li K, Li W, Zou H, Zhao L. Association between FAS 1377 G>A polymorphisms and breast cancer susceptibility: a meta-analysis. Tumour Biol. 2014;35(1):351–6.CrossRefPubMed
56.
Zurück zum Zitat Wang Z, Gu J, Nie W, Xu J, Huang G, Guan X. Quantitative assessment of the association between three polymorphisms in FAS and FASL gene and breast cancer risk. Tumour Biol. 2014;35:3035–9.CrossRefPubMed Wang Z, Gu J, Nie W, Xu J, Huang G, Guan X. Quantitative assessment of the association between three polymorphisms in FAS and FASL gene and breast cancer risk. Tumour Biol. 2014;35:3035–9.CrossRefPubMed
57.
Zurück zum Zitat Chen X, Mo W, Peng Q, Su X. Lack of association between Fas rs180082 polymorphisms and risk of cervical cancer: an update by meta-analysis. BMC Med Genet. 2013;14:71.CrossRefPubMedPubMedCentral Chen X, Mo W, Peng Q, Su X. Lack of association between Fas rs180082 polymorphisms and risk of cervical cancer: an update by meta-analysis. BMC Med Genet. 2013;14:71.CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Zhang Y, Tong S, Guan L, Na F, Zhao W, Wei L. CD95 rs1800682 polymorphisms and cervical cancer risk: evidence from meta-analysis. Tumour Biol. 2014;35:1785–90.CrossRefPubMed Zhang Y, Tong S, Guan L, Na F, Zhao W, Wei L. CD95 rs1800682 polymorphisms and cervical cancer risk: evidence from meta-analysis. Tumour Biol. 2014;35:1785–90.CrossRefPubMed
59.
Zurück zum Zitat Wang GQ, Bao L, Zhao XX, Zhang J, Nan KJ. Associations between Fas/FasL polymorphisms and susceptibility to cervical cancer: a meta-analysis. Tumour Biol. 2014;35:4107–12.CrossRefPubMed Wang GQ, Bao L, Zhao XX, Zhang J, Nan KJ. Associations between Fas/FasL polymorphisms and susceptibility to cervical cancer: a meta-analysis. Tumour Biol. 2014;35:4107–12.CrossRefPubMed
60.
Zurück zum Zitat Zhu J, Lu L, Cheng X, Xie R, Chen Z, Li Y, et al. Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis. Tumour Biol. 2014;35:5137–42.CrossRefPubMed Zhu J, Lu L, Cheng X, Xie R, Chen Z, Li Y, et al. Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis. Tumour Biol. 2014;35:5137–42.CrossRefPubMed
61.
Zurück zum Zitat Tong N, Zhang L, Sheng X, Wang M, Zhang Z, Fang Y, et al. Functional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: a case–control study. Leuk Lymphoma. 2012;53:1360–6.CrossRefPubMed Tong N, Zhang L, Sheng X, Wang M, Zhang Z, Fang Y, et al. Functional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: a case–control study. Leuk Lymphoma. 2012;53:1360–6.CrossRefPubMed
62.
Zurück zum Zitat Zhao H, Zheng L, Li X, Wang L. FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance. Sci Rep. 2014;4:3866.PubMedPubMedCentral Zhao H, Zheng L, Li X, Wang L. FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance. Sci Rep. 2014;4:3866.PubMedPubMedCentral
63.
Zurück zum Zitat Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, Liu G, et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis. 2008;29:2147–52.CrossRefPubMedPubMedCentral Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, Liu G, et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis. 2008;29:2147–52.CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Lei D, Sturgis EM, Wang LE, Liu Z, Zafereo ME, Wei Q, et al. FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2010;19:1484–91.CrossRefPubMedPubMedCentral Lei D, Sturgis EM, Wang LE, Liu Z, Zafereo ME, Wei Q, et al. FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2010;19:1484–91.CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Mahfoudh W, Bouaouina N, Gabbouj S. Chouchane. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the Tunisian population. Hum Immunol. 2012;73:932–8.CrossRefPubMed Mahfoudh W, Bouaouina N, Gabbouj S. Chouchane. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the Tunisian population. Hum Immunol. 2012;73:932–8.CrossRefPubMed
66.
Zurück zum Zitat Xu Y, Deng Q, He B, Pan Y, Li R, Gao T, et al. The diplotype Fas -1377A/-670G as a genetic marker to predict a lower risk of breast cancer in Chinese women. Tumour Biol. 2014;35:9147–61.CrossRefPubMed Xu Y, Deng Q, He B, Pan Y, Li R, Gao T, et al. The diplotype Fas -1377A/-670G as a genetic marker to predict a lower risk of breast cancer in Chinese women. Tumour Biol. 2014;35:9147–61.CrossRefPubMed
67.
Zurück zum Zitat de Carvalho-Neto PB, dos Santos M, de Carvalho MB, Mercante AM, dos Santos VP, Severino P, et al. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity. PLoS One. 2013;8:e69024.CrossRefPubMedPubMedCentral de Carvalho-Neto PB, dos Santos M, de Carvalho MB, Mercante AM, dos Santos VP, Severino P, et al. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity. PLoS One. 2013;8:e69024.CrossRefPubMedPubMedCentral
68.
Zurück zum Zitat Verim L, Timirci-Kahraman O, Akbulut H, Akbas A, Ozturk T, Turan S, et al. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population. In Vivo. 2014;28:397–402.PubMed Verim L, Timirci-Kahraman O, Akbulut H, Akbas A, Ozturk T, Turan S, et al. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population. In Vivo. 2014;28:397–402.PubMed
69.
Zurück zum Zitat Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994;54:1580–6.PubMed Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994;54:1580–6.PubMed
70.
Zurück zum Zitat Mapara MY, Bargou R, Zugck C, Döhner H, Ustaoglu F, Jonker RR, et al. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol. 1993;23:702–8.CrossRefPubMed Mapara MY, Bargou R, Zugck C, Döhner H, Ustaoglu F, Jonker RR, et al. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol. 1993;23:702–8.CrossRefPubMed
71.
Zurück zum Zitat Borset M, Hjorth-Hansen H, Johnsen AC, Seidel C, Waage A, Espevik T, et al. Apoptosis, proliferation and NF-kappaB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor. Eur J Haematol. 1999;63:345–53.CrossRefPubMed Borset M, Hjorth-Hansen H, Johnsen AC, Seidel C, Waage A, Espevik T, et al. Apoptosis, proliferation and NF-kappaB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor. Eur J Haematol. 1999;63:345–53.CrossRefPubMed
72.
Zurück zum Zitat Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res. 2006;12:3705–12.CrossRefPubMed Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res. 2006;12:3705–12.CrossRefPubMed
73.
Zurück zum Zitat Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233–43.CrossRefPubMed Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233–43.CrossRefPubMed
74.
Zurück zum Zitat Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 1992;267:10709–15.PubMed Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 1992;267:10709–15.PubMed
75.
Zurück zum Zitat Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34:577–82.CrossRefPubMed Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34:577–82.CrossRefPubMed
76.
Zurück zum Zitat Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63:4327–30.PubMed Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63:4327–30.PubMed
77.
Zurück zum Zitat Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas −670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 2004;112:1084–5.CrossRefPubMed Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas −670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 2004;112:1084–5.CrossRefPubMed
78.
Zurück zum Zitat Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170:132–8.CrossRefPubMed Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170:132–8.CrossRefPubMed
79.
Zurück zum Zitat Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005;202:967–74.CrossRefPubMedPubMedCentral Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005;202:967–74.CrossRefPubMedPubMedCentral
80.
Zurück zum Zitat Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. J Cancer. 2000;82:1682–8.CrossRef Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. J Cancer. 2000;82:1682–8.CrossRef
81.
Zurück zum Zitat Takagi A, Imai A, Horibe S, Ohno T, Tamaya T. Lack of evidence for expression of Fas ligand in Fas-bearing tumors. Oncol Rep. 1998;5:377–80.PubMed Takagi A, Imai A, Horibe S, Ohno T, Tamaya T. Lack of evidence for expression of Fas ligand in Fas-bearing tumors. Oncol Rep. 1998;5:377–80.PubMed
82.
Zurück zum Zitat Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999;5:3529–33.PubMed Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999;5:3529–33.PubMed
83.
Zurück zum Zitat Kondera-Anasz Z, Mielczarek-Palacz A, Sikora J. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Apoptosis. 2005;10:1143–9.CrossRefPubMed Kondera-Anasz Z, Mielczarek-Palacz A, Sikora J. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Apoptosis. 2005;10:1143–9.CrossRefPubMed
84.
Zurück zum Zitat Hefler L, Mayerhofer K, Nardi A, Reinthaller A, Kainz C, Tempfer C. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol. 2000;96:65–9.PubMed Hefler L, Mayerhofer K, Nardi A, Reinthaller A, Kainz C, Tempfer C. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol. 2000;96:65–9.PubMed
85.
Zurück zum Zitat Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002;29:1183–8.PubMed Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002;29:1183–8.PubMed
86.
Zurück zum Zitat Watson CJ, O’Kane H, Maxwell P, Sharaf O, Petak I, Hyland PL, et al. Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer. Int J Oncol. 2012;40:645–54.PubMed Watson CJ, O’Kane H, Maxwell P, Sharaf O, Petak I, Hyland PL, et al. Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer. Int J Oncol. 2012;40:645–54.PubMed
87.
Zurück zum Zitat Ghanim V, Herrmann H, Heller G, Peter B, Hadzijusufovic E, Blatt K, et al. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood. 2012;119:4242–52.CrossRefPubMed Ghanim V, Herrmann H, Heller G, Peter B, Hadzijusufovic E, Blatt K, et al. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood. 2012;119:4242–52.CrossRefPubMed
88.
Zurück zum Zitat Yurchenko M, Shlapatska LM, Sidorenko SP. The multilevel regulation of CD95 signaling outcome. Exp Oncol. 2012;34:153–9.PubMed Yurchenko M, Shlapatska LM, Sidorenko SP. The multilevel regulation of CD95 signaling outcome. Exp Oncol. 2012;34:153–9.PubMed
89.
Zurück zum Zitat Sancho-Martinez I, Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle. 2009;8:838–42.CrossRefPubMed Sancho-Martinez I, Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle. 2009;8:838–42.CrossRefPubMed
Metadaten
Titel
Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently
verfasst von
Sateesh Reddy Nallapalle
Sarika Daripally
V. T. S Vidudala Prasad
Publikationsdatum
01.04.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2896-7

Weitere Artikel der Ausgabe 4/2015

Tumor Biology 4/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.